Copyright Reports & Markets. All rights reserved.

Global Gabapentin Drug Market Insights, Forecast to 2025

Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Gabapentin Drug Industry
  • 1.7 COVID-19 Impact: Gabapentin Drug Market Trends
  • 2 Global Gabapentin Drug Quarterly Market Size Analysis

    • 2.1 Gabapentin Drug Business Impact Assessment - COVID-19
      • 2.1.1 Global Gabapentin Drug Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
      • 2.1.2 Global Gabapentin Drug Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Gabapentin Drug Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 Global Gabapentin Drug Quarterly Market Size by Manufacturers, 2019 VS 2020
    • 3.2 Global Gabapentin Drug Factory Price by Manufacturers
    • 3.3 Location of Key Manufacturers Gabapentin Drug Manufacturing Factories and Area Served
    • 3.4 Date of Key Manufacturers Enter into Gabapentin Drug Market
    • 3.5 Key Manufacturers Gabapentin Drug Product Offered
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Gabapentin Drug Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Capsule
      • 1.4.2 Tablet
      • 1.4.3 Oral solution
    • 4.2 By Type, Global Gabapentin Drug Market Size, 2019-2021
      • 4.2.1 By Type, Global Gabapentin Drug Market Size by Type, 2020-2021
      • 4.2.2 By Type, Global Gabapentin Drug Price, 2020-2021

    5 Impact of Covid-19 on Gabapentin Drug Segments, By Application

    • 5.1 Overview
      • 5.5.1 Postherpetic neuralgia in adults
      • 5.5.2 Partial onset seizures
      • 5.5.3 Others
    • 5.2 By Application, Global Gabapentin Drug Market Size, 2019-2021
      • 5.2.1 By Application, Global Gabapentin Drug Market Size by Application, 2019-2021
      • 5.2.2 By Application, Global Gabapentin Drug Price, 2020-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Pfizer
      • 7.1.1 Pfizer Business Overview
      • 7.1.2 Pfizer Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.1.3 Pfizer Gabapentin Drug Product Introduction
      • 7.1.4 Pfizer Response to COVID-19 and Related Developments
    • 7.2 Depomed
      • 7.2.1 Depomed Business Overview
      • 7.2.2 Depomed Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.2.3 Depomed Gabapentin Drug Product Introduction
      • 7.2.4 Depomed Response to COVID-19 and Related Developments
    • 7.3 Apotex
      • 7.3.1 Apotex Business Overview
      • 7.3.2 Apotex Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.3.3 Apotex Gabapentin Drug Product Introduction
      • 7.3.4 Apotex Response to COVID-19 and Related Developments
    • 7.4 Teva
      • 7.4.1 Teva Business Overview
      • 7.4.2 Teva Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.4.3 Teva Gabapentin Drug Product Introduction
      • 7.4.4 Teva Response to COVID-19 and Related Developments
    • 7.5 Acella Pharmaceuticals
      • 7.5.1 Acella Pharmaceuticals Business Overview
      • 7.5.2 Acella Pharmaceuticals Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.5.3 Acella Pharmaceuticals Gabapentin Drug Product Introduction
      • 7.5.4 Acella Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.6 Taro
      • 7.6.1 Taro Business Overview
      • 7.6.2 Taro Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.6.3 Taro Gabapentin Drug Product Introduction
      • 7.6.4 Taro Response to COVID-19 and Related Developments
    • 7.7 Sun Pharmaceutical
      • 7.7.1 Sun Pharmaceutical Business Overview
      • 7.7.2 Sun Pharmaceutical Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.7.3 Sun Pharmaceutical Gabapentin Drug Product Introduction
      • 7.7.4 Sun Pharmaceutical Response to COVID-19 and Related Developments
    • 7.8 Glenmark
      • 7.8.1 Glenmark Business Overview
      • 7.8.2 Glenmark Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.8.3 Glenmark Gabapentin Drug Product Introduction
      • 7.8.4 Glenmark Response to COVID-19 and Related Developments
    • 7.9 Amneal Pharmaceuticals
      • 7.9.1 Amneal Pharmaceuticals Business Overview
      • 7.9.2 Amneal Pharmaceuticals Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.9.3 Amneal Pharmaceuticals Gabapentin Drug Product Introduction
      • 7.9.4 Amneal Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.10 Aurobindo Pharma
      • 7.10.1 Aurobindo Pharma Business Overview
      • 7.10.2 Aurobindo Pharma Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.10.3 Aurobindo Pharma Gabapentin Drug Product Introduction
      • 7.10.4 Aurobindo Pharma Response to COVID-19 and Related Developments
    • 7.11 Zydus Pharmaceuticals
      • 7.11.1 Zydus Pharmaceuticals Business Overview
      • 7.11.2 Zydus Pharmaceuticals Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.11.3 Zydus Pharmaceuticals Gabapentin Drug Product Introduction
      • 7.11.4 Zydus Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.12 Hi-Tech Pharmaceuticals
      • 7.12.1 Hi-Tech Pharmaceuticals Business Overview
      • 7.12.2 Hi-Tech Pharmaceuticals Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.12.3 Hi-Tech Pharmaceuticals Gabapentin Drug Product Introduction
      • 7.12.4 Hi-Tech Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.13 Marksans Pharma
      • 7.13.1 Marksans Pharma Business Overview
      • 7.13.2 Marksans Pharma Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.13.3 Marksans Pharma Gabapentin Drug Product Introduction
      • 7.13.4 Marksans Pharma Response to COVID-19 and Related Developments
    • 7.14 Mylan
      • 7.14.1 Mylan Business Overview
      • 7.14.2 Mylan Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.14.3 Mylan Gabapentin Drug Product Introduction
      • 7.14.4 Mylan Response to COVID-19 and Related Developments
    • 7.15 InvaGen Pharmaceuticals
      • 7.15.1 InvaGen Pharmaceuticals Business Overview
      • 7.15.2 InvaGen Pharmaceuticals Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.15.3 InvaGen Pharmaceuticals Gabapentin Drug Product Introduction
      • 7.15.4 InvaGen Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.16 Alkem Laboratories
      • 7.16.1 Alkem Laboratories Business Overview
      • 7.16.2 Alkem Laboratories Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.16.3 Alkem Laboratories Gabapentin Drug Product Introduction
      • 7.16.4 Alkem Laboratories Response to COVID-19 and Related Developments
    • 7.17 Tris Pharma
      • 7.17.1 Tris Pharma Business Overview
      • 7.17.2 Tris Pharma Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.17.3 Tris Pharma Gabapentin Drug Product Introduction
      • 7.17.4 Tris Pharma Response to COVID-19 and Related Developments
    • 7.18 ACI HealthCare Limited
      • 7.18.1 ACI HealthCare Limited Business Overview
      • 7.18.2 ACI HealthCare Limited Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.18.3 ACI HealthCare Limited Gabapentin Drug Product Introduction
      • 7.18.4 ACI HealthCare Limited Response to COVID-19 and Related Developments
    • 7.19 Jiangsu Hengrui Medicine
      • 7.19.1 Jiangsu Hengrui Medicine Business Overview
      • 7.19.2 Jiangsu Hengrui Medicine Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.19.3 Jiangsu Hengrui Medicine Gabapentin Drug Product Introduction
      • 7.19.4 Jiangsu Hengrui Medicine Response to COVID-19 and Related Developments
    • 7.20 CSPC Ouyi Pharmaceutical
      • 7.20.1 CSPC Ouyi Pharmaceutical Business Overview
      • 7.20.2 CSPC Ouyi Pharmaceutical Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.20.3 CSPC Ouyi Pharmaceutical Gabapentin Drug Product Introduction
      • 7.20.4 CSPC Ouyi Pharmaceutical Response to COVID-19 and Related Developments
    • 7.21 Sciegen Pharmaceuticals
      • 7.21.1 Sciegen Pharmaceuticals Business Overview
      • 7.21.2 Sciegen Pharmaceuticals Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.21.3 Sciegen Pharmaceuticals Gabapentin Drug Product Introduction
      • 7.21.4 Sciegen Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.22 Epic Pharma
      • 7.22.1 Epic Pharma Business Overview
      • 7.22.2 Epic Pharma Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.22.3 Epic Pharma Gabapentin Drug Product Introduction
      • 7.22.4 Epic Pharma Response to COVID-19 and Related Developments
    • 7.23 Lupin Limited
      • 7.23.1 Lupin Limited Business Overview
      • 7.23.2 Lupin Limited Gabapentin Drug Quarterly Production and Revenue, 2020
      • 7.23.3 Lupin Limited Gabapentin Drug Product Introduction
      • 7.23.4 Lupin Limited Response to COVID-19 and Related Developments

    8 Supply Chain and Sales Channels Analysis

    • 8.1 Gabapentin Drug Supply Chain Analysis
      • 8.1.1 Gabapentin Drug Supply Chain Analysis
      • 8.1.2 Covid-19 Impact on Gabapentin Drug Supply Chain
    • 8.2 Distribution Channels Analysis
      • 8.2.1 Gabapentin Drug Distribution Channels
      • 8.2.2 Covid-19 Impact on Gabapentin Drug Distribution Channels
      • 8.2.3 Gabapentin Drug Distributors
    • 8.3 Gabapentin Drug Customers

    9 Key Findings

      10 Appendix

      • 10.1 About Us

      This report covers market size and forecasts of Gabapentin Drug, including the following market information:
      Global Gabapentin Drug Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
      Global Gabapentin Drug Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
      Global Gabapentin Drug Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
      Global Gabapentin Drug Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K MT)

      Key market players
      Major competitors identified in this market include Pfizer, Depomed, Apotex, Teva, Acella Pharmaceuticals, Taro, Sun Pharmaceutical, Glenmark, Amneal Pharmaceuticals, Aurobindo Pharma, Zydus Pharmaceuticals, Hi-Tech Pharmaceuticals, Marksans Pharma, Mylan, InvaGen Pharmaceuticals, Alkem Laboratories, Tris Pharma, ACI HealthCare Limited, Jiangsu Hengrui Medicine, CSPC Ouyi Pharmaceutical, Sciegen Pharmaceuticals, Epic Pharma, Lupin Limited, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Capsule
      Tablet
      Oral solution

      Based on the Application:
      Postherpetic neuralgia in adults
      Partial onset seizures
      Others

      Buy now